Fructose leads to hepatic steatosis in zebrafish that is reversed by mechanistic target of rapamycin (mTOR) inhibition

Hepatology

Volumn 60, Issue 5, 2014, Pages 1581-1592

  Sapp, Valerie ^a   Gaffney, Leah ^a   Eauclaire, Steven F ^a   Matthews, Randolph P ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSE; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; RAPAMYCIN; TUNICAMYCIN; VALINOMYCIN; ANTINEOPLASTIC ANTIBIOTIC; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EMBRYO; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIPID LIVER LEVEL; LIPID STORAGE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; FATTY LIVER; HUMAN; MALE; METABOLISM;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE MODELS, ANIMAL; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; FRUCTOSE; HUMANS; MALE; MULTIPROTEIN COMPLEXES; SIROLIMUS; TOR SERINE-THREONINE KINASES; UP-REGULATION; ZEBRAFISH;

EID: 84922234913     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27284     Document Type: Article

References (39)

1. Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract 2011;26:565-576.
2. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45.
3. Gordon-Larsen P, The NS, Adair LS. Longitudinal trends in obesity in the United States from adolescence to the third decade of life. Obesity 2010;18:1801-1804.
4. Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 2007;150:12-17 e2.
5. Skelton JA, Cook SR, Auinger P, Klein JD, Barlow SE. Prevalence and trends of severe obesity among US children and adolescents. Acad Pediatr 2009;9:322-329.
6. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013;162:496-500 e1.
7. Koebnick C, Getahun D, Reynolds K, Coleman KJ, Porter AH, Lawrence JM, et al. Trends in nonalcoholic fatty liver disease-related hospitalizations in US children, adolescents, and young adults. J Pediatr Gastroenterol Nutr 2009;48:597-603.
8. Marriott BP, Cole N, Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J Nutr 2009;139:1228S-12235S.
9. Ouyang X, Cirillo P, Sautin Y, McCall S, Bruchette JL, Diehl AM, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008;48:993-999.
10. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1961-1971.
11. Vos MB, Colvin R, Belt P, Molleston JP, Murray KF, Rosenthal P, et al. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr 2012;54:90-96.
12. Kawasaki T, Igarashi K, Koeda T, Sugimoto K, Nakagawa K, Hayashi S, et al. Rats fed fructose-enriched diets have characteristics of nonalcoholic hepatic steatosis. J Nutr 2009;139:2067-2071.
13. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012;23:203-208.
14. Matthews RP, Lorent K, Manoral-Mobias R, Huang Y, Gong W, Murray IV, et al. TNF{alpha}-dependent hepatic steatosis and liver degeneration caused by mutation of zebrafish s-adenosylhomocysteine hydrolase. Development 2009;136:865-875.
15. Thakur PC, Stuckenholz C, Rivera MR, Davison JM, Yao JK, Amsterdam A, et al. Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis in cdipt-deficient zebrafish. Hepatology 2011;54:452-462.
16. Cinaroglu A, Gao C, Imrie D, Sadler KC. Activating transcription factor 6 plays protective and pathological roles in steatosis due to endoplasmic reticulum stress in zebrafish. Hepatology 2012;54:495-508.
17. Amali AA, Rekha RD, Lin CJ, Wang WL, Gong HY, Her GM, et al. Thioacetamide induced liver damage in zebrafish embryo as a disease model for steatohepatitis. J Biomed Sci 2006;13:225-232.
18. Hammes TO, Pedroso GL, Hartmann CR, Escobar TD, Fracasso LB, da Rosa DP, et al. The effect of taurine on hepatic steatosis induced by thioacetamide in zebrafish (Danio rerio). Dig Dis Sci 2011;57:675-682.
19. Tainaka T, Shimada Y, Kuroyanagi J, Zang L, Oka T, Nishimura Y, et al. Transcriptome analysis of anti-fatty liver action by Campari tomato using a zebrafish diet-induced obesity model. Nutr Metab 2011;8:88.
20. Suzuki M, Shinohara Y, Fujimoto T. Histochemical detection of lipid droplets in cultured cells. Methods Mol Biol 2013;931:483-491.
21. Eauclaire SF, Cui S, Ma L, Matous J, Marlow FL, Gupta T, et al. Mutations in vacuolar H(+)-ATPase subunits lead to biliary developmental defects in zebrafish. Dev Biol 2012;365:434-444.
22. Cui S, Capecci LM, Matthews RP. Disruption of planar cell polarity activity leads to developmental biliary defects. Dev Biol 2011;351:229-241.
23. Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in nonalcoholic steatohepatitis. Adv Clin Chem 2013;61:67-125.
24. Day CP, James OF. Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998;27:1463-1466.
25. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005;22(Suppl 2):71-73.
26. Tsedensodnom O, Vacaru AM, Howarth DL, Yin C, Sadler KC. Ethanol metabolism and oxidative stress are required for unfolded protein response activation and steatosis in zebrafish with alcoholic liver disease. Dis Model Mech 2013;6:1213-1226.
27. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev 2005;6:439-448.
28. Kashima J, Shintani-Ishida K, Nakajima M, Maeda H, Unuma K, Uchiyama Y, et al. Immunohistochemical study of the autophagy marker microtubule-associated protein 1 light chain 3 in normal and steatotic human livers. Hepatol Res. 2013 [Epub ahead of print].
29. Sharma S, Mells JE, Fu PP, Saxena NK, Anania FA. GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. PLoS One 2011;6:e25269.
30. Dann SG, Selvaraj A, Thomas G. mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007;13:252-259.
31. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
32. Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, Balderas E, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 2011;146:408-420.
33. Li F, Yin Y, Tan B, Kong X, Wu G. Leucine nutrition in animals and humans: mTOR signaling and beyond. Amino Acids 2011;41:1185-1193.
34. Wang Y, Shi M, Fu H, Xu H, Wei J, Wang T, et al. Mammalian target of the rapamycin pathway is involved in non-alcoholic fatty liver disease. Mol Med Rep 2010;3:909-915.
35. Lin CW, Zhang H, Li M, Xiong X, Chen X, Dong XC, et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice. Journal of hepatology. 2013;58:993-999.
36. Wang CY, Stapleton DS, Schueler KL, Rabaglia ME, Oler AT, Keller MP, et al. Tsc2, a positional candidate gene underlying a quantitative trait locus for hepatic steatosis. J Lipid Res 2012;53:1493-1501.
37. Li S, Ogawa W, Emi A, Hayashi K, Senga Y, Nomura K, et al. Role of S6K1 in regulation of SREBP1c expression in the liver. Biochem Biophys Res Commun 2011;412:197-202.
38. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 2011;14:21-32.
39. Kenerson HL, Yeh MM, Yeung RS. Tuberous sclerosis complex-1 deficiency attenuates diet-induced hepatic lipid accumulation. PLoS One. 2011;6:e18075.